Top prognostic signatures in ER+/HER2− high proliferation.

Significance Analysis of Prognostic Signatures

Beck, Andrew H
Knoblauch, Nicholas W.
Hefti, Marco
Kaplan, Jennifer
Schnitt, Stuart Jay
Culhane, Aedin
Schroeder, Markus S.
Risch, Thomas
Quackenbush, John
Haibe-Kains, Benjamin

October 2016

A major goal in translational cancer research is to identify biological signatures driving cancer pr...

A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories.

Székely, Borbála
Iwamoto T
Szász, Attila Marcell
Qi Y
Matsuoka J
Symmans WF
Tőkés, Anna-Mária
Kulka, Janina
Swanton C
Pusztai L

February 2016

The goal of this study was to assess the prognostic value of a 3-gene (TOP2A, FOXM1, and MKI67) prol...

ER−/HER2− Venn diagram and scatterplot.

Andrew H. Beck (254596)
Nicholas W. Knoblauch (276487)
Marco M. Hefti (276488)
Jennifer Kaplan (276489)
Stuart J. Schnitt (276490)
Aedin C. Culhane (276491)
Markus S. Schroeder (276492)
Thomas Risch (183849)
John Quackenbush (1213)
Benjamin Haibe-Kains (183845)

January 2013

(A) The gene sets significant by at least one of the P values at the 0.05 level are displa...

Top prognostic signatures in ER+/HER2 low proliferation.

Andrew H. Beck (254596)
Nicholas W. Knoblauch (276487)
Marco M. Hefti (276488)
Jennifer Kaplan (276489)
Stuart J. Schnitt (276490)
Aedin C. Culhane (276491)
Markus S. Schroeder (276492)
Thomas Risch (183849)
John Quackenbush (1213)
Benjamin Haibe-Kains (183845)

January 2013

Gene sets in the analysis come from the Broad institute's MSigDB. These gene sets can be further ...

Top prognostic signatures in HER2+.

Andrew H. Beck (254596)
Nicholas W. Knoblauch (276487)
Marco M. Hefti (276488)
Jennifer Kaplan (276489)
Stuart J. Schnitt (276490)
Aedin C. Culhane (276491)
Markus S. Schroeder (276492)
Thomas Risch (183849)
John Quackenbush (1213)
Benjamin Haibe-Kains (183845)

January 2013

Gene sets in the analysis come from the Broad institute's MSigDB. These gene sets can be further ...

Top prognostic signatures in global breast cancer.

Andrew H. Beck (254596)
Nicholas W. Knoblauch (276487)
Marco M. Hefti (276488)
Jennifer Kaplan (276489)
Stuart J. Schnitt (276490)
Aedin C. Culhane (276491)
Markus S. Schroeder (276492)
Thomas Risch (183849)
John Quackenbush (1213)
Benjamin Haibe-Kains (183845)

January 2013

Gene sets in the analysis come from the Broad institute's MSigDB. These gene sets can be further ...

Top prognostic signatures in Non-angiogenic overall.

Andrew H. Beck (254596)
Nicholas W. Knoblauch (276487)
Marco M. Hefti (276488)
Jennifer Kaplan (276489)
Stuart J. Schnitt (276490)
Aedin C. Culhane (276491)
Markus S. Schroeder (276492)
Thomas Risch (183849)
John Quackenbush (1213)
Benjamin Haibe-Kains (183845)

January 2013

Gene sets in the analysis come from the Broad institute's MSigDB. These gene sets can be further ...

Top prognostic signatures in Angiogenic overall.

Andrew H. Beck (254596)
Nicholas W. Knoblauch (276487)
Marco M. Hefti (276488)
Jennifer Kaplan (276489)
Stuart J. Schnitt (276490)
Aedin C. Culhane (276491)
Markus S. Schroeder (276492)
Thomas Risch (183849)
John Quackenbush (1213)
Benjamin Haibe-Kains (183845)

January 2013

Gene sets in the analysis come from the Broad institute's MSigDB. These gene sets can be further ...

ER+/HER2− high proliferation Venn diagram and scatterplot.

Andrew H. Beck (254596)
Nicholas W. Knoblauch (276487)
Marco M. Hefti (276488)
Jennifer Kaplan (276489)
Stuart J. Schnitt (276490)
Aedin C. Culhane (276491)
Markus S. Schroeder (276492)
Thomas Risch (183849)
John Quackenbush (1213)
Benjamin Haibe-Kains (183845)

January 2013

(A) The gene sets significant by at least one of the P values at the 0.05 level are displa...

Identification of cell proliferation, immune response and cell migration as critical pathways in a prognostic signature for HER2+:ERα- breast cancer.

Jeffrey C Liu
Miriam Zacksenhouse
Andrea Eisen
Sharon Nofech-Mozes
Eldad Zacksenhaus

January 2017

Multi-gene prognostic signatures derived from primary tumor biopsies can guide clinicians in designi...

Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application.

Enora Laas
Peter Mallon
Francois P Duhoux
Amina Hamidouche
Roman Rouzier
Fabien Reyal

BACKGROUND:Numerous prognostic gene expression signatures have been recently described. Among the si...

Estrogen receptor-positive breast cancer subsets by gene set enrichment analysis

Christina Yau (62337)
Vita Fedele (62338)
Ritu Roydasgupta (48201)
Jane Fridlyand (810)
Alan Hubbard (20757)
Joe W Gray (42232)
Karen Chew (62339)
Shanaz H Dairkee (62340)
Dan H Moore (25852)
Francesco Schittulli (62341)
Stefania Tommasi (62342)
Angelo Paradiso (8377)
Donna G Albertson (7210)
Christopher C Benz (62343)

December 2011

Copyright information:Taken from "Aging impacts transcriptomes but not genomes of h...

ER+/HER2− low proliferation Venn diagram and scatterplot.

Andrew H. Beck (254596)
Nicholas W. Knoblauch (276487)
Marco M. Hefti (276488)
Jennifer Kaplan (276489)
Stuart J. Schnitt (276490)
Aedin C. Culhane (276491)
Markus S. Schroeder (276492)
Thomas Risch (183849)
John Quackenbush (1213)
Benjamin Haibe-Kains (183845)

January 2013

(A) The gene sets significant by at least one of the P values at the 0.05 level are displa...

Predicting risk of breast cancer recurrence using gene-expression profiling.

Ignatiadis, Michalis
Desmedt, Christine

January 2007

The molecular profiling of breast tumors using the powerful microarray technology has uncovered the ...

Prediction of breast cancer prognosis using gene set statistics provides signature stability and biological context

Abraham, G
Kowalczyk, A
Loi, S
Haviv, I
Zobel, J

May 2010

BACKGROUND: Different microarray studies have compiled gene lists for predicting outcomes of a range...

Significance Analysis of Prognostic Signatures

Beck, Andrew H
Knoblauch, Nicholas W.
Hefti, Marco
Kaplan, Jennifer
Schnitt, Stuart Jay
Culhane, Aedin
Schroeder, Markus S.
Risch, Thomas
Quackenbush, John
Haibe-Kains, Benjamin

October 2016

A major goal in translational cancer research is to identify biological signatures driving cancer pr...

A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories.

Székely, Borbála
Iwamoto T
Szász, Attila Marcell
Qi Y
Matsuoka J
Symmans WF
Tőkés, Anna-Mária
Kulka, Janina
Swanton C
Pusztai L

February 2016

The goal of this study was to assess the prognostic value of a 3-gene (TOP2A, FOXM1, and MKI67) prol...

ER−/HER2− Venn diagram and scatterplot.

Andrew H. Beck (254596)
Nicholas W. Knoblauch (276487)
Marco M. Hefti (276488)
Jennifer Kaplan (276489)
Stuart J. Schnitt (276490)
Aedin C. Culhane (276491)
Markus S. Schroeder (276492)
Thomas Risch (183849)
John Quackenbush (1213)
Benjamin Haibe-Kains (183845)

January 2013

(A) The gene sets significant by at least one of the P values at the 0.05 level are displa...

Top prognostic signatures in ER+/HER2 low proliferation.

Andrew H. Beck (254596)
Nicholas W. Knoblauch (276487)
Marco M. Hefti (276488)
Jennifer Kaplan (276489)
Stuart J. Schnitt (276490)
Aedin C. Culhane (276491)
Markus S. Schroeder (276492)
Thomas Risch (183849)
John Quackenbush (1213)
Benjamin Haibe-Kains (183845)

January 2013

Gene sets in the analysis come from the Broad institute's MSigDB. These gene sets can be further ...

Top prognostic signatures in HER2+.

Andrew H. Beck (254596)
Nicholas W. Knoblauch (276487)
Marco M. Hefti (276488)
Jennifer Kaplan (276489)
Stuart J. Schnitt (276490)
Aedin C. Culhane (276491)
Markus S. Schroeder (276492)
Thomas Risch (183849)
John Quackenbush (1213)
Benjamin Haibe-Kains (183845)

January 2013

Gene sets in the analysis come from the Broad institute's MSigDB. These gene sets can be further ...

Top prognostic signatures in global breast cancer.

Andrew H. Beck (254596)
Nicholas W. Knoblauch (276487)
Marco M. Hefti (276488)
Jennifer Kaplan (276489)
Stuart J. Schnitt (276490)
Aedin C. Culhane (276491)
Markus S. Schroeder (276492)
Thomas Risch (183849)
John Quackenbush (1213)
Benjamin Haibe-Kains (183845)

January 2013

Gene sets in the analysis come from the Broad institute's MSigDB. These gene sets can be further ...

Top prognostic signatures in Non-angiogenic overall.

Andrew H. Beck (254596)
Nicholas W. Knoblauch (276487)
Marco M. Hefti (276488)
Jennifer Kaplan (276489)
Stuart J. Schnitt (276490)
Aedin C. Culhane (276491)
Markus S. Schroeder (276492)
Thomas Risch (183849)
John Quackenbush (1213)
Benjamin Haibe-Kains (183845)

January 2013

Gene sets in the analysis come from the Broad institute's MSigDB. These gene sets can be further ...

Top prognostic signatures in Angiogenic overall.

Andrew H. Beck (254596)
Nicholas W. Knoblauch (276487)
Marco M. Hefti (276488)
Jennifer Kaplan (276489)
Stuart J. Schnitt (276490)
Aedin C. Culhane (276491)
Markus S. Schroeder (276492)
Thomas Risch (183849)
John Quackenbush (1213)
Benjamin Haibe-Kains (183845)

January 2013

Gene sets in the analysis come from the Broad institute's MSigDB. These gene sets can be further ...

ER+/HER2− high proliferation Venn diagram and scatterplot.

Andrew H. Beck (254596)
Nicholas W. Knoblauch (276487)
Marco M. Hefti (276488)
Jennifer Kaplan (276489)
Stuart J. Schnitt (276490)
Aedin C. Culhane (276491)
Markus S. Schroeder (276492)
Thomas Risch (183849)
John Quackenbush (1213)
Benjamin Haibe-Kains (183845)

January 2013

(A) The gene sets significant by at least one of the P values at the 0.05 level are displa...

Identification of cell proliferation, immune response and cell migration as critical pathways in a prognostic signature for HER2+:ERα- breast cancer.

Jeffrey C Liu
Miriam Zacksenhouse
Andrea Eisen
Sharon Nofech-Mozes
Eldad Zacksenhaus

January 2017

Multi-gene prognostic signatures derived from primary tumor biopsies can guide clinicians in designi...

Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application.

Enora Laas
Peter Mallon
Francois P Duhoux
Amina Hamidouche
Roman Rouzier
Fabien Reyal

BACKGROUND:Numerous prognostic gene expression signatures have been recently described. Among the si...

Estrogen receptor-positive breast cancer subsets by gene set enrichment analysis

Christina Yau (62337)
Vita Fedele (62338)
Ritu Roydasgupta (48201)
Jane Fridlyand (810)
Alan Hubbard (20757)
Joe W Gray (42232)
Karen Chew (62339)
Shanaz H Dairkee (62340)
Dan H Moore (25852)
Francesco Schittulli (62341)
Stefania Tommasi (62342)
Angelo Paradiso (8377)
Donna G Albertson (7210)
Christopher C Benz (62343)

December 2011

Copyright information:Taken from "Aging impacts transcriptomes but not genomes of h...

ER+/HER2− low proliferation Venn diagram and scatterplot.

Andrew H. Beck (254596)
Nicholas W. Knoblauch (276487)
Marco M. Hefti (276488)
Jennifer Kaplan (276489)
Stuart J. Schnitt (276490)
Aedin C. Culhane (276491)
Markus S. Schroeder (276492)
Thomas Risch (183849)
John Quackenbush (1213)
Benjamin Haibe-Kains (183845)

January 2013

(A) The gene sets significant by at least one of the P values at the 0.05 level are displa...

Predicting risk of breast cancer recurrence using gene-expression profiling.

Ignatiadis, Michalis
Desmedt, Christine

January 2007

The molecular profiling of breast tumors using the powerful microarray technology has uncovered the ...

Prediction of breast cancer prognosis using gene set statistics provides signature stability and biological context

Abraham, G
Kowalczyk, A
Loi, S
Haviv, I
Zobel, J

May 2010

BACKGROUND: Different microarray studies have compiled gene lists for predicting outcomes of a range...

Significance Analysis of Prognostic Signatures

Beck, Andrew H
Knoblauch, Nicholas W.
Hefti, Marco
Kaplan, Jennifer
Schnitt, Stuart Jay
Culhane, Aedin
Schroeder, Markus S.
Risch, Thomas
Quackenbush, John
Haibe-Kains, Benjamin

October 2016

A major goal in translational cancer research is to identify biological signatures driving cancer pr...

A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories.

Székely, Borbála
Iwamoto T
Szász, Attila Marcell
Qi Y
Matsuoka J
Symmans WF
Tőkés, Anna-Mária
Kulka, Janina
Swanton C
Pusztai L

February 2016

The goal of this study was to assess the prognostic value of a 3-gene (TOP2A, FOXM1, and MKI67) prol...

ER−/HER2− Venn diagram and scatterplot.

Andrew H. Beck (254596)
Nicholas W. Knoblauch (276487)
Marco M. Hefti (276488)
Jennifer Kaplan (276489)
Stuart J. Schnitt (276490)
Aedin C. Culhane (276491)
Markus S. Schroeder (276492)
Thomas Risch (183849)
John Quackenbush (1213)
Benjamin Haibe-Kains (183845)

January 2013

(A) The gene sets significant by at least one of the P values at the 0.05 level are displa...

Top prognostic signatures in ER+/HER2− high proliferation.

Abstract

Extracted data

Top prognostic signatures in ER+/HER2− high proliferation.

Abstract

Extracted data

Related items

Related items